Pulse Journal Club Active Debates Trending Explore Researchers

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Home Explore Journal Club Trending

⌘+K

B2B Symposium on Innovative Technologies in Bladder Cancer | Synapse

February 11, 2026Open Access

B2B Symposium on Innovative Technologies in Bladder Cancer

Key Points

To discuss and present cutting-edge technologies related to bladder cancer treatment and management.
Organized a symposium featuring experts in uro-oncology.
Facilitated discussions on the latest innovations and research in bladder cancer.
Live broadcast of the event through the SIU@U Congress app.
Engaged participants in conversations about emerging technologies in bladder cancer care.
Provided a platform for sharing new findings and techniques in the field.

Abstract

The 7th Bench-to-Bedside Uro-Oncology: GU Cancers Triad Meeting, organized in conjunction with the 45th Annual Congress of the Société Internationale d’Urologie, was held on 31 October 2025, in Edinburgh, Scotland, and transmitted live on the SIU@U Congress app ...

Ask AI

Mark Helpful

Bookmark

Relay

View Full Paper

Ask AI

Mark Helpful

Bookmark

Relay

View Full Paper

Cite This Study

Black et al. (Mon,) studied this question.

synapsesocial.com/papers/698c1c8e267fb587c655f170 https://doi.org/https://doi.org/10.3390/siuj7010004

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1P2-02 PIVOTAL RESULTS FROM BOND-003: A PHASE 3, SINGLE-ARM STUDY OF INTRAVESICAL CRETOSTIMOGENE GRENADENOREPVEC FOR THE TREATMENT OF HIGH RISK, BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU2024 · 26 citations
2Flexible Cystoscopy and Holmium:Yttrium Aluminum Garnet Laser Ablation for Recurrent Nonmuscle Invasive Bladder Carcinoma Under Local Anesthesia2013 · 19 citations
3Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study2023 · 56 citations
4SunRISe-1: Phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin who are ineligible for or decline radical cystectomy.2022 · 11 citations
5Duration of response (DoR) following treatment with UGN-102 in patients with recurrent, low-grade, intermediate-risk, non-muscle invasive, bladder cancer: 18-month DoR data from the phase 3 ENVISION trial.2025 · 2 citations